Multicentric carpotarsal osteolysis syndrome

Multicentric carpotarsal osteolysis syndrome
Other namesMCTO[1]
This condition is inherited in an autosomal dominant manner.
SpecialtyMedical genetics

Multicentric carpotarsal osteolysis syndrome (MCTO) is a rare autosomal dominant condition.[2] This condition is also known as idiopathic multicentric osteolysis with nephropathy. It is characterised by carpal-tarsal destruction and kidney failure.

Signs and symptoms

The presentation is of gradual loss of the small bones in the carpus and tarsus. This may lead to joint subluxation and instability. The kidney failure, when present, usually presents as the presence of protein in the urine.

In some cases, there may also be craniofacial abnormalities including[citation needed]

Histology of renal biopsies show glomerulosclerosis and severe tubulointerstitial fibrosis.

Intellectual disability may occur.

Genetics

This condition is caused by mutations in the transcription factor MafB, or V-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB), gene.[3] This gene encodes a basic leucine zipper (bZIP) transcription factor.

The gene is located on the long arm of chromosome 20 (20q11.2-q13.1).

Pathogenesis

How this mutation causes the clinical picture is not currently clear.[citation needed]

Diagnosis

The diagnosis may be suspected on the basis of the constellation of clinical features. It is made by sequencing the MAFB gene.

Classification

This condition has been classified into five types.[4]

  • Type 1: hereditary multicentric osteolysis with dominant transmission
  • Type 2: hereditary multicentric osteolysis with recessive transmission
  • Type 3: nonhereditary multicentric osteolysis with nephropathy
  • Type 4: Gorham–Stout syndrome

Differential diagnosis

The condition should be differentially diagnosed from juvenile rheumatoid arthritis and other genetic skeletal dysplasias as Multicentric Osteolysis, Nodulosis, and Arthropathy.[5][6]

Treatment

Optimal treatment for this condition is unclear. Bisphosphonates and denosumab may be of use for the bone lesions. Cyclosporine A may be of use for treating the nephropathy. Steroids and other immunosuppressant drugs do not seem to be of help.

History

This condition was first described by Shurtleff et al. in 1964.[2]

References

  1. ^ "OMIM Entry - # 166300 - MULTICENTRIC CARPOTARSAL OSTEOLYSIS SYNDROME; MCTO". omim.org. Retrieved 27 April 2019.
  2. ^ a b Shurtleff DB, Sparkes RS, Clawson DK, Guntheroth WG, Mottet NK (1964) Hereditary osteolysis with hypertension and nephropathy. JAMA 188:363–368
  3. ^ Zankl A, Duncan EL, Leo PJ, Clark GR, Glazov EA, Addor M-C, Herlin T, Kim CA, Leheup BP, McGill J, McTaggart S, Mittas S, Mitchell, AL, Mortier GR, Robertson SP, Schroeder M, Terhal P, Brown MA (2012) Multicentric carpotarsal osteolysis is caused by mutations clustering in the amino-terminal transcriptional activation domain of MAFB. Am J Hum Genet 90: 494-501
  4. ^ Hardegger F, Simpson LA, Segmueller G (1985) The syndrome of idiopathic osteolysis. Classification, review, and case report. J Bone Joint Surg Br 67(1):88-93
  5. ^ Bhavani, GS; Shah, H; Shukla, A; Gupta, N; Gowrishankar, K; Rao, AP; Kabra, M; Agarwal, M; Ranganath, P; Ekbote, AV; Phadke, SR; Kamath, A; Dalal, A; Girisha, KM (February 2016). "Clinical and mutation profile of multicentric osteolysis nodulosis and arthropathy". American Journal of Medical Genetics. Part A. 170A (2): 410–417. doi:10.1002/ajmg.a.37447. PMID 26601801.
  6. ^ Elsebaie, H; Mansour, MA; Elsayed, SM; Mahmoud, S; El-Sobky, TA (December 2021). "Multicentric Osteolysis, Nodulosis, and Arthropathy in two unrelated children with matrix metalloproteinase 2 variants: Genetic-skeletal correlations". Bone Reports. 15: 101106. doi:10.1016/j.bonr.2021.101106. PMC 8283316. PMID 34307793.